Remove 2015 Remove Pharmacokinetics Remove Small Molecule
article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs.

article thumbnail

Game-changing pan-TEAD inhibitor for solid tumours

Drug Target Review

The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharma Money on the Move: October 21-27

The Pharma Data

million in 2015. Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer. The $71 million funding includes an initial financing of $32.5 In the U.S., The company’s $27.4

article thumbnail

ATICAPRANT

New Drug Approvals

14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 18] In February 2015, Cerecor Inc. 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 18] In February 2015, Cerecor Inc. 11 December 2015. 2] Aticaprant is taken by mouth. [1] nM vs. 24.0 mg dose and 94% for a 10 mg dose.

article thumbnail

Analysis Life Sciences Thank You Workshop addresses oncology dose optimization across full span of development

Agency IQ

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This workshop built on three prior workshops held by the FDA-AACR, which took place in 2015, 2016 and 2017. . …

Science 40
article thumbnail

Analysis Life Sciences Thank You The FDA and oncology: 2023 year in review

Agency IQ

In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules. Dose optimization for oncology products has been an issue flagged for improvement even prior to the creation of OCE.

FDA 40
article thumbnail

The FDA Modernization Act 2.0: The End of IND-Enabling Toxicology Studies?

The Premier Consulting Blog

In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA. Summary basis of approval (SBA) for Aristada (NDA 207533, 10/5/2015), [link] [accessed 23 March 2023]. 7] Clinical Implications Although the changes implemented by the FDA Modernization Act 2.0

FDA 52